Analytical Data
-
Gene name
SLC51B
- Application
-
Alternative Names
OST-B; OSTbeta; OST-beta; Solute carrier family 51 subunit beta
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q86UW2
-
Expression Region
Arg57~Ser128
-
Molecular Weight
15kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC51B, also known as the small intestine-bile acid transporter (SIBAT), is part of the solute carrier family involved in the transport of bile acids across cell membranes. This protein is primarily expressed in the epithelial cells of the intestine and plays a crucial role in the enterohepatic circulation of bile acids, which are essential for lipid digestion and absorption. Recent studies have highlighted its significance in various physiological processes, including lipid metabolism, gut health, and the regulation of cholesterol levels. Dysregulation of SLC51B has been linked to several metabolic disorders, such as obesity, non-alcoholic fatty liver disease (NAFLD), and inflammatory bowel diseases. Research into SLC51B focuses on understanding its structural and functional properties, the mechanisms underlying its transport activity, and its potential as a therapeutic target for metabolic diseases. Innovative techniques, including molecular biology and biochemical assays, are employed to elucidate the pathways and regulatory networks involving SLC51B. Furthermore, studies on the effects of certain dietary components on SLC51B function may provide insights into nutritional strategies for managing metabolic health. As a result, SLC51B not only represents a critical player in bile acid homeostasis but also holds promise for the development of novel interventions aimed at improving metabolic health and preventing related diseases.
